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ESBLAbstract The aim of this study was to investigate the prevalence of ESBL and MBL encoding
genes among A. baumannii isolates. In this cross sectional study, 100 A. baumannii strains were iso-
lated from ICU wards of 3 educational hospitals of Hamadan City, Iran in 2011. Phenotypic iden-
tiﬁcation of the production of ESBLs and MBLs has been carried out by using E-test and DDST
methods, respectively. PCR technique was used for ampliﬁcation of the ESBL and MBL encoding
genes, namely: CTX-M, SHV, TEM, OXA-51, VIM-Family, IMP-Family, SPM-1, SIM-1, and
GIM-1. Eighty seven (87%), 95 (95%), 98 (98%) and 95 (95%) out of 100 A. baumannii isolates
were resistant to imipenem, meropenem, ceftazidime and cefotaxime, respectively. Also, 99% and
7% of the isolates were MBLs and ESBLs produced phenotypically. Thirty (30%), 20 (20%) and
58 (58%) out of 100 A. baumannii isolates have been conﬁrmed to harbor the blaVIM-family,
TEM and SHV genes, respectively. Our results show no signiﬁcant relationship between the
detected gens with production of MBLs and ESBLs in spite of high prevalence of MBL encoding
ESBL and MBL encoding genes in Acinetobacter baumannii strains 425and drug resistant A. baumannii. Probably some other genes rather than what we studied are
involved in phenotypic production of MBLs and ESBLs and subsequent drug resistance in Hama-
dan area, Iran.
ª 2015 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acinetobacter baumannii is an opportunistic pathogen, with
the following characteristics of being Gram-negative, oxi-
dase-negative, non-fermentative, nonmotile coccobacilli and
is an unknown natural reservoir and has broad range of
antibiotic resistance. The bacterium is prevalent in most
places especially in hospitals and other health care institutes
(Perez et al., 2007; Yeom et al., 2013; Poirel et al., 2011).
Over the last 30 years, Acinetobacter genus has been faced
with considerable changes in its taxonomic place (Peleg
et al., 2008). High morbidity and mortality are the charac-
teristics of nosocomial infections caused by Acinetobacter
spp., which included urinary tract, skin and soft tissue
infections, pneumonia and bacteremia especially in patients
with severe health conditions (Karageorgopoulos et al.,
2008; Safari et al., 2013; Kuo et al., 2012). Most studies
conducted by researchers on this bacterium have been car-
ried out concentrating on its drug resistant aspects, which
is a major factor limiting the treatment of nosocomial
infections (Poirel et al., 2011; Cerqueira and Peleg, 2011).
During the last two decades, the advent and widespread
dissemination of bacterial infections resistant to beta-lac-
tams, especially to 3rd generation of cephalosporins and
carbapenems, has become a globally signiﬁcant problem
(Pfeifer et al., 2010). Metallo beta lactamases (MBLs) are
sorts of powerful enzymes called carbapenemases responsi-
ble for antibiotic resistance (Bush, 2001). Four groups of
these enzymes have been described in A. baumannii, includ-
ing IMP-like, SIM-1, NDM-type and VIM-like carbapene-
mases (Poirel et al., 2011, 2010). Genetic characteristic of
MBLs-encoding A. baumannii isolates revealed the presence
of blaSIM, blaIMP and blaVIM genes (Poirel et al., 2011).
Extended-spectrum ß-lactamases (ESBLs) are encoded by
TEM-type, SHV-type and CTX-M-type genes, which are
subjected to phonotypical resistance to penicillins and 3rd
generation cephalosporins (Pfeifer et al., 2010). ESBLs are
mostly plasmid-mediated and most are parts of the
TEM and SHV families of enzymes (Mehrgan and
Rahbar, 2008).
One of the notable carbapenem-resistance mechanisms
is caused by carbapenem-hydrolyzing b-lactamases, carba-
penemases. In addition, the metallo-b-lactamases (MbLs)
paly a crucial role in drug resistance against carbapenems
(Poirel and Nordmann, 2006). Also, the extended-spec-
trum b-lactamases, ESBLs, play an important role in
resistance against later generation cephalosporins such
as cefepime, cefotaxime and ceftazidime (Zhanel et al.,
2013).
The aim of this study was to investigate the prevalence of
ESBLs and MBLs encoding genes and drug resistance against
meropenem, imipenem, ceftazidime and cefotaximeamongA. bau-
mannii isolates.2. Materials and methods
2.1. Sampling and isolation of bacteria
The study was a cross sectional study initiated in June 2011 by
collecting 100 non-duplicate A. baumannii isolates from clinical
specimens from ICU ward patients hospitalized in three educa-
tional hospitals of Hamadan City in Iran. The sampling was
conducted for 17 months and the isolates were almost from
74 tracheal aspirate, 16 blood, 5 urine, 4 sputum and 1 wound
samples. The identiﬁcation of the isolates has been accom-
plished by biochemical tests and conﬁrmed by tracking the bla-
OXA-51 -like carbapenemase gene, which is intrinsic to this
species, using single PCR (Turton et al., 2006). The conﬁrmed
A. baumannii isolates were kept frozen at 70 C for further
tests.
2.2. Antibiogram
Susceptibility to meropenem, imipenem, ceftazidime and cefo-
taxime (Mast CO, UK) was tested by Kirby-Bauer disk diffu-
sion method. The antibiogram procedure was performed as the
manufacturer constructed. In brief, 1.5 · 108 CFU of bacterial
suspension, equivalent to McFarland Turbidity Standard No.
0.5, was transferred on Muller-Hinton agar medium (Merck,
Germany) and antibiogram disks containing meropenem
(10 lg), imipenem (10 lg), ceftazidime (30 lg) and cefotaxime
(30 lg) were placed on the medium. Then, the media were
incubated for 18 h at 35 C. The results were interpreted
according to the recommendations of the Clinical and Labora-
tory Standards Institute (CLSI) (CLSI, 2007). A control strain
of Pseudomonas aeruginosa ATCC 27853 was used for quality
control of susceptibility testing.
2.3. Phenotypic MBL detection
For determination of phenotypic MbL production among the
bacterial isolates, MIC Test Strips (Lioﬂichem Italy) contain-
ing imipenem and imipenem plus EDTA were used. The E-test
procedure was performed according to the manufacturer’s
manual. Reduction in the MIC of imipenem of P3 dilutions
in the presence of EDTA is regarded as a positive result. Also,
A. baumannii strain was considered MbL producer if a phan-
tom zone or deformation of the ellipse was obviously observed.
2.4. Phenotypic identiﬁcation of ESBL producing isolates
Phenotypic identiﬁcation of ESBL producing isolates have
been carried out using DDST screening method. Antibiogram
disks containing ceftazidime (30 lg), cefotaxime (30 lg), ceft-
azidime (30 lg) + clavulanic acid (10 lg) and cfotaxime
(30 lg) + clavulanic (10 lg) were used. Pairs of disks
(ceftazidime with ceftazidime/clavulanic acid and cefotaxime
Table 1 Primers used for PCR ampliﬁcation of the studied genes.
Primer name Primer sequence (50 to 30) Annealing temp (C) Product size (bp) Reference
CTX-M F:TCTTCCAGAATAAGGAATCCC 51 909 Kalai Blagui et al. (2007)
R:CCGTTTCCGCTATTACAAAC
SHV F: CTTTACTCGCTTTATCG 53 868 Kolar et al. (2010)
R: TCCCGCAGATAAATCAC
TEM F:ATGAGTATTCAACATTTCCG 53 931 Kalai Blagui et al. (2007)
R:CCAATGCTTAATCAGTGAGC
OXA-51 F:TAATGCTTTGATCGGCCTTG 52 353 Turton et al. (2006)
R:TGG ATTGCACTTCATCTTGG
VIM-Family F: GATGGTGTTTGGTCGCATA 52 390 Ellington et al. (2007)
R: CGA ATGCGCAGCACCAG
IMP-Family F: GGAATAGAGTGGCTTAAYTCTC 52 188 Ellington et al. (2007)
R: CCA AACYACTASGTTATCT
SPM-1 F:AAAATCTGGGTACGCAAACG 54 271 Ellington et al., 2007
R:ACATTATCCGCTGGAACAGG
SIM-1 F:TAC AAGGGATTCGGCATCG 54 570 Ellington et al. (2007)
R: TAATGGCCTGTTCCCATGTG
GIM-1 F: TCG ACACACCTTGGTCTGAA 54 477 Ellington et al. (2007)
426 M. Safari et al.with cfotaxime /clavulanic) were placed on Muller-Hinton
agar medium (Merck, Germany) with 20 mm space between
them. According to the CLSI criteria and manufacturer
instruction, the P5 mm inhibition zone of growth in
ceftazidime/clavulanic acid and cfotaxime/clavulanic than
ceftazidime and cfotaxime was regarded as an isolate that is
producing ESBLs.
2.5. Ampliﬁcation of blaOXA-51-like gene
The bacterial DNA was extracted by the alkaline lysis method
(Kheyrodin and Ghazvinian, 2012). The pair of blaOXA-51 prim-
ers (Bioneer Korea); OXA-F 50-TAATGCTTTGATCGGC
CTTG-30, and OXA-R 50-TGGATTGCACTTCATCTTGG-
30 were used for PCR detection of the genes (Turton et al.,
2006). PCR ampliﬁcation procedure was performed using
25 ll of master mix containing 0.2 ll of Taq polymerase 5 U/
ll, 2.5 ll of 10XPCR buffer along with MgCl2, 1 ll of 10 pM
from each reverse and forward primers, 2.5 ll of dNTPs MIX
(2 Mm), 3 ll of DNA template, 14.8 ll of DNase-Free and
RNase-Free Distilled Water. PCR ampliﬁcation was done in
the thermal cycler device. Agarose gel electrophoresis of the
ampliﬁed DNA product with 100 bp size marker (Fermentas,
Korea) was carried out in a 2% agarose gel for 2 h at 80 V and
stainedwith ethidiumbromide tomanifest and detect the 353 bp
band. Also, PCR reaction contained positive and negative con-
trol. The A. baumannii carrying blaOXA-51-like gene (obtained
from Dr. Bahador, Tehran University of Medical Sciences,
Tehran, Iran) was used as the positive control.
2.6. Ampliﬁcation of ESBL genes
The speciﬁc primers (Bioneer Korea) including CTX-M,
SHV and TEM (Table 1) were used for PCR ampliﬁcation
of the genes (Ellington et al., 2007; Kalai Blagui et al., 2007;
Kolar et al., 2010; Turton et al., 2006). PCR ampliﬁcation pro-
cedure was performed with 25 ll of master mix containing
0.2 ll of Taq polymerase 5 U/ll, 2.5 ll of 10· PCR buffer
along with MgCl2, 1 ll of 10 pM from each reverse and for-
ward primers, 2.5 ll of dNTPs MIX (2 Mm), 3 ll of DNAtemplate,14.8 ll of DNase-Free and RNase-Free Distilled
Water. PCR ampliﬁcation was done in the thermal cycler
device. Agarose gel electrophoresis of the ampliﬁed DNA
product with 100 bp size marker (Fermentas, Korea) was
carried out in a 2% agarose gel for 2 h at 80 V and stained with
ethidium bromide.
2.7. Ampliﬁcation of MBL genes
The speciﬁc primers (Bioneer Korea) including VIM-Family,
IMP-Family, SPM-1, SIM-1 and GIM-1 (Table 1) were used
for PCR ampliﬁcation of the genes (Ellington et al., 2007).
PCR ampliﬁcation procedure was performed with 25 ll of
master mix containing 0.2 ll of Taq polymerase 5 U/ll,
2.5 ll of 10X PCR buffer along with MgCl2, 1 ll of 10 pM
from each reverse and forward primers, 2.5 ll of dNTPs
MIX (2 Mm), 3 ll of DNA template,14.8 ll of DNase-Free
and RNase-Free Distilled Water. PCR ampliﬁcation was done
in the thermal cycler device. Agarose gel electrophoresis of the
ampliﬁed DNA product with 100 bp size marker (Fermentas,
Korea) was carried out in a 2% agarose gel for 2 h at 80 V and
stained with ethidium bromide.
2.8. Statistical analysis
Statistical results were calculated by the Statistical Package for
the Social Sciences (SPSS Inc., USA) version 16.0 for windows
and also, using McNemar and Chi square tests regarding
P 6 0.05 as signiﬁcance level.3. Results
A. baumannii isolates were conﬁrmed with microbiological and
PCR (bla-OXA-51) methods and entered to the study (Fig. 1).
3.1. Antibiogram
Susceptibility to meropenem, imipenem, ceftazidime and
cefotaxime was evaluated by the Kirby-Bauer disk diffusion
Figure 1 PCR results for ampliﬁcation of blaOXA-51 gene in A.
baumannii isolates; Lane 1:100 bp DNA ladder; Lane 2: negative
control; Lane 3: Positive control; Lanes 4, 5 different isolates
harboring blaOXA-51-like gene. Table 2 Frequency of the studied genes among 100 A.
baumannii isolates.
Gene PCR results
Positive N (%) Negative N (%)
SHV 58 (58) 42 (42)
TEM 20 (20) 80 (80)
CTX-M 0 (0) 100 (100)
VIM-Family 30 (30) 70 (70)
IM-Family 0 (0) 100 (100)
SIM 0 (0) 100 (100)
SPM 0 (0) 100 (100)
GIM 0 (0) 100 (100)
igure 2 PCR product gel electrophoresis; a: 100 bp DNA
dder template of the company; b: PCR results for ampliﬁcation
f blaVIM-family genes in A. baumannii isolates; Lane 1:100 bp
NA ladder; Lane 2: negative control; Lane 3, Positive control;
anes 4, 8 different isolates harboring blaVIM-family gene.
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A. baumannii isolates were resistant to imipenem, meropenem,
ceftazidime and cefotaxime, respectively.
3.2. Phenotypic MBL detection
For determination of phenotypic MbL production among iso-
lates, MIC Test strips containing imipenem and imipenem
along with EDTA were used. Ninety nine percent out of 100
A. baumannii isolates were MBL producing.
3.3. Phenotypic identiﬁcation of ESBL producing isolates
Phenotypic identiﬁcation of ESBL producing isolates have
been carried out using DDST screening method. From total
of 100 samples, 7% A. baumannii isolates identiﬁed to be pro-
duce ESBL enzymes.
3.4. Detection of ESBL–SHV, -CTX-M and -TEM genes
Of all 100 A. baumannii isolates, 58%, and 20% isolates were
harboring HSV, and CTX-M genes, respectively. The TEM
gene was not found in the studied strains. There was no statis-
tically signiﬁcant relationship between the cefotaxime and ceft-
azidime resistance and presence of SHV, CTX-M genes in the
isolates.
3.5. Detection of VIM-Family, IMP-Family, SPM-1, SIM-1
and GIM-1genes
Thirty percent out of 100 A. baumannii isolates has been con-
ﬁrmed to harbor the blaVIM-family genes (Fig. 2), but the other
genes including IMP-Family, SPM-1, SIM-1 and GIM-1 haveF
la
o
D
Lnot been detected (Table 2). No signiﬁcant relationship was
observed between the presence and absence of blaVIM-family
genes in the isolates’ resistance to imipenem and meropenem.
4. Discussion
Production of carbapenem-hydrolyzing b-lactamases, also
called carbapenemases, is one of the signiﬁcant mechanisms
of carbapenem resistance, in which Methalo b-lactamases
(MbLs) possess the principal role in drug resistance against
carbapenems (Poirel and Nordmann, 2006). Also, the
extended-spectrum b-lactamases, ESBLs, play an important
role in resistance against later generation cephalosporins such
as cefotaxime, ceftazidime, and cefepime (Zhanel et al., 2013).
In this study, the prevalence of ESBLs and MBLs encoding
genes and drug resistance against meropenem, imipenem, ceft-
azidime and cefotaxime among A. baumannii isolates has been
investigated showing a high resistance rate among the
antibiotics.
Totally 100 A. baumannii isolates have been examined for 3
ESBLs and 5 MBLs encoding genes. Three out of eight genes
have been detected including SHV (58%), TEM (20%) and
428 M. Safari et al.VIM (30%). None of the other studied genes has been detected
among 100 isolates of A. baumannii, which were isolated from
ICU wards of 3 educational Hospitals, Hamadan City, Iran,
2011. Also, no signiﬁcant relationship has been observed about
the presence of the detected ESBL and MBL encoding genes
with phonotypical resistance against imipenem, meropenem,
cefotaxime and ceftazidime. Eighty seven percent, 95%, 98%
and 95% out of 100 A. baumannii isolates were resistant to imi-
penem, meropenem, ceftazidime and cefotaxime, respectively.
The results showed that most of the A. baumannii isolates
were producing MBLs (99%), but not ESBLs (7%). There
was not any signiﬁcant relationship about phonotypic ESBL
and MBL producing and the detected genes. Reports from
Iran illustrate the high prevalence of drug resistance and multi
drug resistance in A. baumannii especially against most effec-
tive antibiotics such as imipenem and meropenem (Feizabadi
et al., 2008; Peymani et al., 2011). Ting et al. (2013) investi-
gated the drug resistance genes in 7 strains of imipenem-resis-
tant A. baumannii including TEM, SHV, CTX-M, DHA, CIT,
IMP, VIM, KPC, OXA-23. They detected TEM (100%) and
OXA-23 (100%) genes among the isolates, but the other genes
such as SHV, CTX-M, DHA, CIT, IMP, VIM, KPC could not
be detected from 7 strains of imipenem-resistant A. baumannii.
In the present study, consistent with Ting et al. (2013), just
some of the genes have been detected including SHV (58%),
TEM (20%) and VIM (30%). In another study by
Shahcheraghi et al. (2011) in Tehran, Iran, they showed that
the MBL encoding genes included bla VIM-2, bla SPM-1,
bla IMP-2, bla GES-1, bla OXA-51, bla OXA-23 genes among
203 A. baumannii isolates. They reported that 6 isolates pro-
duce MBLs and 94 isolates produce OXA-type carbapenem-
ase. Their ﬁnding suggests that in Tehran the prevalence of
MBLs producing A. baumannii strains is lower than that of
the present study from Hamadan City. They detect blaSPM-1,
blaGES-1, blaOXA-51, blaOXA-23 genes among 6, 2, 94 and 84 iso-
lates of the bacterium, respectively (Shahcheraghi et al., 2011).
The previous research by Rezaee et al. (2013) revealed genes
coding for IMP, SPM-1, VIM, PER-1, VEB-1, TEM, SHV,
GES-1, and CTX-M among 76 Acinetobacter spp. Also, they
reported that 37% of isolates carried at least one of the bla-
PER-1 or blaTEM-1 genes and 13.15% of their studied isolates
reported to harbor blaTEM-1 gene, which is similar to that of
the present study (20%). Also, none of their studied A. bau-
mannii isolates were harboring for blaVEB-1, blaSHV-, blaCTX-
M-2 and blaGES-1 (Rezaee et al., 2013). In our study, none of
the following genes, CTX-M, IMP, SIM, SPM, and GIM,
has been detected among 100 isolates of A. baumannii.
Our results show that there was not any signiﬁcant relation-
ship between the detected genes with production of MBLs and
ESBLs. Probably, some other genes rather than what we stud-
ied are involved in phenotypic production of MBLs and
ESBLs and the subsequent drug resistance in Hamadan, Iran.
5. Conclusion
Despite the high prevalence of phenotypic MBL production
and high resistance rate against imipenem and meropenem
A. baumannii isolates, lower rates of MBL encoding genes have
been detected. Also, the high resistance rate against ceftazi-
dime and cefotaxime was not in relation with phenotypic
and genotypic ESBL production. Probably some other genesrather than what we studied are involved in phenotypic pro-
duction of MBLs and ESBLs and subsequent high drug resis-
tance in Hamadan, Iran.
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